Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

LiveWell mBC-pilotti RCT

perjantai 13. marraskuuta 2026 päivittänyt: Kelly Hyland, Medical University of South Carolina

LiveWell mBC: Mukautetun dialektisen behavioraalisen terapian taitojen koulutusohjelman pilottitesti metastaattista rintasyöpää sairastavien naisten ryhmissä

In this pilot randomized controlled trial, women with metastatic breast cancer and at least mild distress (N=48) will be randomized to receive LiveWell mBC, a group-based adapted Dialectical Behavioral Therapy (DBT) Skills Training protocol, or Usual Care. The investigators will evaluate feasibility, acceptability, and preliminary efficacy of LiveWell to reduce distress (primary outcome) and improve psychological well-being, symptom burden, and quality of life (secondary outcomes).

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Participants will be randomized 2:1 to receive LiveWell mBC, an adapted DBT Skills Training intervention delivered to small groups of women with mBC via telehealth, or usual care. LiveWell mBC involves orientation + an 8-session skills training protocol of mindfulness, emotion regulation, distress tolerance and interpersonal effectiveness.

Participants will complete self-report measures at baseline, mid-intervention (Week 5), post-intervention (Week 11) and 1 month post-intervention (Week 15). It is hypothesized that: 1) RCT methods will demonstrate evidence of feasibility (>70% overall retention rate, >70% LiveWell mBC completion rate); 2) RCT methods will demonstrated evidence of acceptability (>50% enrollment rate, >80% participant satisfaction); and 3) LiveWell participants will demonstrate reductions in distress (primary outcome) compared to Usual Care at 11-week follow-up.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

48

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

  • Nimi: Benjamin Axelrod
  • Puhelinnumero: 843-876-2645
  • Sähköposti: axelrod@musc.edu

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Nainen

Kuvaus

Inclusion Criteria:

  1. identify as female
  2. be diagnosed with metastatic (AJCC stage IV) breast cancer
  3. be receiving care for metastatic breast cancer at Hollings Cancer Center
  4. endorse >3 out of 10 on the NCCN distress thermometer over the past week plus at least one emotional concern on the problem checklist
  5. be > 18 years of age
  6. be able to understand, speak, and read English
  7. be able to provide informed consent.

Exclusion Criteria:

  1. reported or suspected cognitive impairment
  2. presence of untreated serious mental illness (e.g., schizophrenia) indicated by the medical chart or treating oncologist
  3. expected survival <6 months, as indicated by a hospice referral

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Tukevaa hoitoa
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Ei väliintuloa: Usual Care

Will receive a handout with general support resources available at Hollings Cancer Center.

Kokeellinen: LiveWell mBC: A Group-Based Adapted Dialectical Behavioral Therapy Skills Training Program

Will receive 9 telehealth-delivered small group (6-8 participants) sessions (orientation + 8 session DBT skills training protocol) co-facilitated by two skills trainers. Sessions will be 90 minutes each and delivered approximately weekly. Sessions will teach skills from dialectical behavioral therapy (e.g., mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness) adapted for patients with metastatic breast cancer. Sessions follow a standardized structure, including 1) mindfulness practice, 2) home practice and diary card review, 3) learning and practicing new skills, and 4) closing ritual. Participants will have access to a resource library of skills training videos and mindfulness recordings.

LiveWell mBC: A Group-Based Adapted Dialectical Behavioral Therapy Skills Training Program

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
PROMIS Depression Short Form (8a)
Aikaikkuna: Baseline (week 0), post-intervention (week 11), and 1-month follow-up (week 15)

Depression will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression (8 items) Short Form Scale. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater depressive symptomology.

Baseline (week 0), post-intervention (week 11), and 1-month follow-up (week 15)
PROMIS Anxiety Short Form (7a)
Aikaikkuna: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

Anxiety will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety (7 items) Short Form Scale. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater anxiety symptomology.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Intolerance of Uncertainty Scale - Short Form (IUS-12)
Aikaikkuna: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

The 12-item Intolerance of Uncertainty Scale (IUS) Short Form will be used to measure emotional, cognitive, and behavioral reactions to uncertain situations. The IUS has a score range of 12-60, where a higher score indicates greater intolerance of uncertainty.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
Peace, Equanimity, and Acceptance in the Cancer (PEACE) - Peaceful Acceptance of Illness Subscale
Aikaikkuna: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

The 5-item Peace, Equanimity, and Acceptance in the Cancer (PEACE) - Peaceful Acceptance of Illness Subscale will be used to assess patient-reported acceptance, inner peace, and tranquility in the context of cancer. The subscale has a score range of 5-20, where a higher score indicates greater peaceful acceptance of illness.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
PROMIS Positive Affect Short Form (15a)
Aikaikkuna: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

The PROMIS Positive Affect Short Form 15a will be used to assess patient-reported positive emotions and well-being over the past 7 days. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater positive affect.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
Difficulty in Regulating Emotions Scale (DERS-18)
Aikaikkuna: Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)

The DERS-18 will be used to assess emotion dysregulation. The DERS-18 has a score range of 18-80, where a higher score indicates greater difficulty with regulating emotions.

Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
Aikaikkuna: Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)

The 10-item Cognitive and Affective Mindfulness Scale-Revised will be used to assess patient-reported mindfulness qualities, including present-moment awareness, acceptance, and attention. The CAMS-R has a score range of 10-40, where a higher score indicates greater mindfulness.

Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
DBT Ways of Coping Checklist (DBT-WCCL) - DBT Skills Subscale (DSS)
Aikaikkuna: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

The DBT Ways of Coping Checklist (DBT-WCCL) -DBT Skills Subscale (DSS) will be used to assess patient-reported frequency of skill use to manage difficult situations. The DBT-WCCL has a score range of 0 to 4, where a higher score indicates greater DBT skill use.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
NCI Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (NCI-PRO-CTCAE)
Aikaikkuna: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

The NCI-PRO-CTCAE will be used to assess patient-reported symptom frequency, severity, and interference related to breast cancer and its treatment. Items are rated on a 5-point Likert scale, with higher scores indicating greater symptom burden.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
PROMIS Self-Efficacy for Managing Emotions Short Form (8a)
Aikaikkuna: Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)

The PROMIS Self-Efficacy for Managing Emotions 8-item Short Form will be used to assess patient-reported confidence in managing negative emotions and emotional distress related to chronic illness. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater self-efficacy for managing emotions.

Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
PROMIS Self-Efficacy for Managing Symptoms Short Form (8a)
Aikaikkuna: Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)

The PROMIS Self-Efficacy for Managing Symptoms 8-item Short Form will be used to assess patient-reported confidence in managing symptoms and limiting their interference with daily life. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater self-efficacy for managing symptoms.

Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
Functional Assessment of Cancer Therapy - Breast (FACT-B)
Aikaikkuna: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

The FACT-B will be used to assess patient-reported quality of life across physical, social/family, emotional, and functional domains, as well as breast cancer-specific concerns. Items are rated on a 5-point Likert scale (0 = Not at all to 4 = Very much) and summed to form subscale and total scores. Higher subscale and total scores indicate better quality of life.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
PROMIS Emotional Support
Aikaikkuna: Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

The PROMIS Emotional Support (4a) Short Form will assess social support. The PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater access to social support networks.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
Group Therapy Experience Scale
Aikaikkuna: Post-intervention (week 11)

The Group Therapy Experience Scale will measure perceived cohesion, self-disclosure, and satisfaction with group therapy. The 16 item scale uses a Likert scale with responses ranging from 1(strongly disagree) to 5(strongly agree). Higher scores indicate higher satisfaction with group therapy.

Post-intervention (week 11)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Yhteistyökumppanit

Tutkijat

  • Päätutkija: Kelly Hyland, PhD, Medical University of South Carolina

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Maanantai 30. marraskuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Perjantai 30. huhtikuuta 2027

Opintojen valmistuminen (Arvioitu)

Maanantai 31. toukokuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 13. huhtikuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 13. huhtikuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Maanantai 20. huhtikuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 17. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 13. marraskuuta 2026

Viimeksi vahvistettu

Maanantai 1. kesäkuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa